Citi Remains Bullish on Argenx SE (ARGX)

Argenx SE (NASDAQ:ARGX) is one of the most profitable biotech stocks to buy. Citi analyst Samantha Semenkow maintained a Buy rating on Argenx SE (NASDAQ:ARGX) on October 23 and set a price target of $1,041. Argenx SE (NASDAQ:ARGX) also received a rating update from Bank of America Securities analyst Tazeen Ahmad, who reiterated a Buy rating on the stock and lifted the price target to $942 from $887.

Ahmad based the positive rating on the company’s strong performance and the growth potential of its Vyvgart medication. The analyst stated that Argenx SE (NASDAQ:ARGX) reported impressive Q2 revenues for Vyvgart, exceeding expectations with a 20% quarter-over-quarter growth.

The Q3 revenue is expected to surpass $1 billion, supported by the drug’s expansion into new geographical regions and the approval of a prefilled syringe, which is anticipated to boost its usage and accessibility.

Argenx SE (NASDAQ:ARGX) is a biotech company that develops treatments for severe autoimmune diseases. The company operates through four segments: the United States, Japan, EMEA, and China.

While we acknowledge the potential of ARGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.